Evaluation of efficacy and safety of anti-sclerostin antibody romosozumab for osteoporosis in patients undergoing hemodialysis
Not Applicable
- Conditions
- osteoporosis, end stage renal disease
- Registration Number
- JPRN-UMIN000037579
- Lead Sponsor
- Tokai University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percent change from baseline in bone mineral density at month 12
- Secondary Outcome Measures
Name Time Method Monthly serum calcium and phosphate levels Serum intact PTH, FGF23, BAP and TRACP5b levels at month 1, month 3, month 6, month 9 and month 12 Percent change of aortic calcification score from baseline